Clinical Trial Update: Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis [NA]

View source ↗

Summary

A completed clinical trial comparing safety and tolerability of AKST1210 at two blood flow rates in subjects with end-stage renal disease on hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• AKST1210

Snippet

Sponsor: Alkahest, Inc. | Conditions: End-Stage Renal Disease | NA | Status: COMPLETED | Results posted: 2023-09-29